stage III or IV irrespective of CD4 cell count, or at any WHO stage with CD4 cell counts ≤ 350 cells/µl. Results Of the 4827 adults patients included in the analysis, 32.1% were male and the median age was 43 years. 67.9% were female and the median age was 41 years. 94.9% of patient were HAART naïve, 5.1% were transfer in. 3913(81.1%) of 4827 patients were still on HAART after 5 years of follow-up. 18.9% difference is attributed to lost to follow-up, patient transferred out and reported deaths. Among the patients with adherence assessment reported, 96.6% of patients had adherence level > 95%, 1.5% had adherence level of 85%-95% and 1% had adherence < 85%. 74.5% patients received their HAART refills at the CDDP, 23.8% received refills at the facility, and 1.4% received refills at their homes. Conclusions These positive results after 5 years of initiating HAART in patients with advanced HIV disease demonstrate efficacy of HAART in resource-limited settings. Additional support is required to ensure timely HAART among adults.